Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
MYRIAD GENETICS INC incurred credit facility of $200 million term loan credit facility with OrbiMed Royalty & Credit Opportunities IV, LP at the greater of the one-month SOFR Rate and 2.50% plus 6.50% maturing July 31, 2030.
- Instrument
- credit facility
- Principal
- $200 million term loan credit facility
- Counterparty
- OrbiMed Royalty & Credit Opportunities IV, LP
- Rate
- the greater of the one-month SOFR Rate and 2.50% plus 6.50%
- Maturity
- July 31, 2030
- Event
- incurrence
Exact text from the filing
On July 31, 2025 (the “Closing Date”), Myriad Genetics, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) with the lenders from time to time party thereto (“Lenders”), and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent (in such capacity, “Administrative Agent”) and as initial lender, consisting of a $200 million term loan credit facility with an initial term loan (the “Initial Loan”) in a maximum principal amount of $125 million, which amount was funded on the Closing Date, and delayed draw term loans (the “Delayed Draw Loans” and together with the Initial Loan, the “Loans”) at the election of the Company on or prior to June 30, 2027, in a maximum principal amount of $75 million (the “Credit Facility”).
View on SEC.gov